O	0	5	First
O	5	6	-
O	6	10	line
O	11	20	treatment
O	21	23	of
O	24	32	advanced
O	33	39	breast
O	40	46	cancer
O	47	51	with
B-intervention	52	61	sunitinib
I-intervention	62	64	in
I-intervention	65	76	combination
I-intervention	77	81	with
I-intervention	82	91	docetaxel
O	92	98	versus
B-control	99	108	docetaxel
I-control	109	114	alone
O	114	115	:
O	116	123	results
O	124	126	of
O	127	128	a
O	129	140	prospective
O	140	141	,
O	142	152	randomized
O	153	158	phase
O	159	162	III
O	163	168	study
O	168	169	.

O	170	172	To
O	173	184	investigate
O	185	192	whether
O	193	202	sunitinib
O	203	207	plus
O	208	217	docetaxel
O	218	226	improves
O	227	235	clinical
O	236	244	outcomes
O	245	248	for
B-eligibility	249	257	patients
I-eligibility	258	262	with
I-eligibility	263	268	human
I-eligibility	269	278	epidermal
I-eligibility	279	285	growth
I-eligibility	286	292	factor
I-eligibility	293	301	receptor
I-eligibility	302	303	2
I-eligibility	304	305	(
I-eligibility	305	309	HER2
I-eligibility	309	310	)
I-eligibility	310	311	/
I-eligibility	311	314	neu
I-eligibility	314	315	-
I-eligibility	315	323	negative
I-eligibility	324	332	advanced
I-eligibility	333	339	breast
I-eligibility	340	346	cancer
I-eligibility	347	348	(
I-eligibility	348	351	ABC
I-eligibility	351	352	)
O	353	359	versus
O	360	369	docetaxel
O	370	375	alone
O	375	376	.

O	377	379	In
O	380	384	this
O	385	390	phase
O	391	394	III
O	395	400	study
O	400	401	,
O	402	410	patients
O	411	415	were
O	416	424	randomly
O	425	433	assigned
O	434	436	to
O	437	441	open
O	441	442	-
O	442	447	label
O	448	459	combination
O	460	467	therapy
O	468	469	(
O	469	478	sunitinib
O	479	481	37
O	481	482	.
O	482	483	5
O	484	486	mg
O	486	487	/
O	487	488	d
O	488	489	,
O	490	494	days
O	495	496	2
O	497	499	to
O	500	502	15
O	503	508	every
O	509	510	3
O	511	516	weeks
O	516	517	;
O	518	521	and
O	522	531	docetaxel
O	532	534	75
O	535	537	mg
O	537	538	/
O	538	539	m
O	539	540	(
O	540	541	2
O	541	542	)
O	542	543	,
O	544	547	day
O	548	549	1
O	550	555	every
O	556	557	3
O	558	563	weeks
O	563	564	)
O	565	567	or
O	568	579	monotherapy
O	580	581	(
O	581	590	docetaxel
O	591	594	100
O	595	597	mg
O	597	598	/
O	598	599	m
O	599	600	(
O	600	601	2
O	601	602	)
O	603	608	every
O	609	610	3
O	611	616	weeks
O	616	617	)
O	617	618	.

B-outcome-Measure	619	630	Progression
I-outcome-Measure	630	631	-
I-outcome-Measure	631	635	free
I-outcome-Measure	636	644	survival
I-outcome-Measure	645	646	(
I-outcome-Measure	646	649	PFS
I-outcome-Measure	649	650	)
O	651	654	was
O	655	658	the
O	659	666	primary
O	667	670	end
O	671	676	point
O	676	677	.

B-intervention-participants	678	681	Two
I-intervention-participants	682	689	hundred
I-intervention-participants	690	696	ninety
I-intervention-participants	696	697	-
I-intervention-participants	697	700	six
O	701	709	patients
O	710	714	were
O	715	723	randomly
O	724	732	assigned
O	733	735	to
O	736	747	combination
O	748	755	therapy
O	755	756	,
O	757	760	and
B-control-participants	761	764	297
O	765	773	patients
O	774	778	were
O	779	787	assigned
O	788	790	to
O	791	802	monotherapy
O	802	803	.

B-outcome	804	810	Median
I-outcome	811	814	PFS
I-outcome	815	820	times
O	821	825	were
B-iv-cont-median	826	827	8
I-iv-cont-median	827	828	.
I-iv-cont-median	828	829	6
O	830	833	and
B-cv-cont-median	834	835	8
I-cv-cont-median	835	836	.
I-cv-cont-median	836	837	3
I-cv-cont-median	838	844	months
O	845	849	with
O	850	861	combination
O	862	869	therapy
O	870	873	and
O	874	885	monotherapy
O	885	886	,
O	887	899	respectively
O	900	901	(
O	901	907	hazard
O	908	913	ratio
O	913	914	,
O	915	916	0
O	916	917	.
O	917	919	92
O	919	920	;
O	921	924	one
O	924	925	-
O	925	930	sided
O	931	932	P
O	933	934	=
O	935	936	.
O	936	939	265
O	939	940	)
O	940	941	.

O	942	945	The
B-outcome	946	955	objective
I-outcome	956	964	response
I-outcome	965	969	rate
I-outcome	970	971	(
I-outcome	971	974	ORR
I-outcome	974	975	)
O	976	979	was
O	980	993	significantly
O	994	1000	higher
O	1001	1005	with
O	1006	1009	the
O	1010	1021	combination
O	1022	1023	(
B-iv-bin-percent	1023	1025	55
I-iv-bin-percent	1025	1026	%
O	1026	1027	)
O	1028	1032	than
O	1033	1037	with
O	1038	1049	monotherapy
O	1050	1051	(
B-cv-bin-percent	1051	1053	42
I-cv-bin-percent	1053	1054	%
O	1054	1055	;
O	1056	1059	one
O	1059	1060	-
O	1060	1065	sided
O	1066	1067	P
O	1068	1069	=
O	1070	1071	.
O	1071	1074	001
O	1074	1075	)
O	1075	1076	.

B-outcome	1077	1085	Duration
I-outcome	1086	1088	of
I-outcome	1089	1097	response
O	1098	1101	was
O	1102	1109	similar
O	1110	1112	in
O	1113	1117	both
O	1118	1122	arms
O	1123	1124	(
B-iv-cont-median	1124	1125	7
I-iv-cont-median	1125	1126	.
I-iv-cont-median	1126	1127	5
I-iv-cont-median	1128	1134	months
O	1135	1139	with
O	1140	1143	the
O	1144	1155	combination
O	1156	1157	v
B-cv-cont-median	1158	1159	7
I-cv-cont-median	1159	1160	.
I-cv-cont-median	1160	1161	2
I-cv-cont-median	1162	1168	months
O	1169	1173	with
O	1174	1185	monotherapy
O	1185	1186	)
O	1186	1187	.

B-outcome	1188	1194	Median
I-outcome	1195	1202	overall
I-outcome	1203	1211	survival
I-outcome	1212	1213	(
I-outcome	1213	1215	OS
I-outcome	1215	1216	)
I-outcome	1217	1222	times
O	1223	1227	were
B-iv-cont-median	1228	1230	24
I-iv-cont-median	1230	1231	.
I-iv-cont-median	1231	1232	8
O	1233	1236	and
B-cv-cont-median	1237	1239	25
I-cv-cont-median	1239	1240	.
I-cv-cont-median	1240	1241	5
I-cv-cont-median	1242	1248	months
O	1249	1253	with
O	1254	1265	combination
O	1266	1273	therapy
O	1274	1277	and
O	1278	1289	monotherapy
O	1289	1290	,
O	1291	1303	respectively
O	1304	1305	(
O	1305	1308	one
O	1308	1309	-
O	1309	1314	sided
O	1315	1316	P
O	1317	1318	=
O	1319	1320	.
O	1320	1323	904
O	1323	1324	)
O	1324	1325	.

O	1326	1331	There
O	1332	1336	were
B-iv-bin-abs	1337	1340	107
B-outcome	1341	1347	deaths
O	1348	1352	with
O	1353	1356	the
O	1357	1368	combination
O	1369	1372	and
B-cv-bin-abs	1373	1375	91
O	1376	1382	deaths
O	1383	1387	with
O	1388	1399	monotherapy
O	1399	1400	.

O	1401	1404	The
O	1405	1414	frequency
O	1415	1417	of
O	1418	1424	common
B-outcome	1425	1432	adverse
I-outcome	1433	1439	events
I-outcome	1440	1441	(
I-outcome	1441	1444	AEs
I-outcome	1444	1445	)
O	1446	1449	was
O	1450	1456	higher
O	1457	1461	with
O	1462	1465	the
O	1466	1477	combination
O	1477	1478	,
O	1479	1481	as
O	1482	1486	were
O	1487	1496	treatment
O	1497	1513	discontinuations
O	1514	1520	caused
O	1521	1523	by
O	1524	1527	AEs
O	1527	1528	.

O	1529	1532	The
O	1533	1544	combination
O	1545	1547	of
O	1548	1557	sunitinib
O	1558	1562	plus
O	1563	1572	docetaxel
O	1573	1581	improved
B-outcome	1582	1585	ORR
O	1586	1589	but
O	1590	1593	did
O	1594	1597	not
O	1598	1605	prolong
O	1606	1612	either
B-outcome	1613	1616	PFS
I-outcome	1617	1619	or
I-outcome	1620	1622	OS
O	1623	1631	compared
O	1632	1636	with
O	1637	1646	docetaxel
O	1647	1652	alone
O	1653	1657	when
O	1658	1663	given
O	1664	1666	to
O	1667	1669	an
O	1670	1680	unselected
O	1681	1685	HER2
O	1685	1686	/
O	1686	1689	neu
O	1689	1690	-
O	1690	1698	negative
O	1699	1705	cohort
O	1706	1708	as
O	1709	1714	first
O	1714	1715	-
O	1715	1719	line
O	1720	1729	treatment
O	1730	1733	for
O	1734	1737	ABC
O	1737	1738	.

O	1739	1748	Sunitinib
O	1749	1760	combination
O	1761	1768	therapy
O	1769	1772	may
O	1773	1777	also
O	1778	1782	have
O	1783	1791	resulted
O	1792	1794	in
B-outcome	1795	1798	AEs
O	1799	1803	that
O	1804	1809	yield
O	1810	1812	an
O	1813	1824	unfavorable
O	1825	1829	risk
O	1829	1830	-
O	1830	1837	benefit
O	1838	1843	ratio
O	1843	1844	.

O	1845	1848	The
O	1849	1858	sunitinib
O	1858	1859	-
O	1859	1868	docetaxel
O	1869	1876	regimen
O	1877	1886	evaluated
O	1887	1889	in
O	1890	1894	this
O	1895	1900	study
O	1901	1903	is
O	1904	1907	not
O	1908	1919	recommended
O	1920	1923	for
O	1924	1931	further
O	1932	1935	use
O	1936	1938	in
O	1939	1942	ABC
O	1942	1943	.
